Five hospitals in England and Wales have switched to urine test, rather than invasive hospital procedure ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice ...

Bladder cancer is often mistaken for UTIs with a urologist outliningg a list of 'painless' symptoms you should never ignore.

Apollo Cancer Centres launches Shield™ Multi-Cancer Detection, a blood-based test that can detect signs of multiple cancers ...

OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The ...

Zydus Lifesciences and Apollo Hospitals are rolling out Shield MCD in India for eligible adults aged 45 and above. The launch ...